Secondary Logo

Journal Logo

February 1, 2022 - Volume 36 - Issue 2

  • JA Levy

    Roel A. Coutinho
    Sarah L. Rowland-Jones
    Michael S. Saag
  • 0269-9370
  • 1473-5571
  • 15 / year
  • 14 of 36 Virology
    32 of 92 Infectious Diseases
    84 of 162 Immunology
  • 4.177

​​​New Special Issue

AIDS V35 Suppl 2 S127 image.jpg

We are pleased to announce the supplement publication  "Antiretroviral treatment optimization – 2021 and beyond"a collection of articles in a special issue of the journal, AIDS.

What have we learned from antiretroviral treatment optimization efforts over the last 5 years? A reflection on progress made in guiding regimen changes to public health programmes, and the challenges facing selection of newer agents.

Supplement Editors: Francois W.D. Venter and Andrew Hill

Figure: Younger age and unemployment predicted poorer adherence in ADVANCE. McCluskey et al. AIDS 35(Suppl. 2):S127-S135.

Current Issue Highlights

Sexually transmitted infections and depot medroxyprogesterone acetate do not impact protection from simian HIV acquisition by long-acting cabotegravir in macaques

Vishwanathan, Sundaram Ajay; Zhao, Chunxia; Luthra, Roopa; More

AIDS. 36(2):169-176, February 1, 2022.

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment

Swindells, Susan; Lutz, Thomas; Van Zyl, Lelanie; More

AIDS. 36(2):185-194, February 1, 2022.

Prevalent human papillomavirus infection increases the risk of HIV acquisition in African women: advancing the argument for human papillomavirus immunization

Liu, Gui; Mugo, Nelly R.; Brown, Elizabeth R.; More

AIDS. 36(2):257-265, February 1, 2022.